Premium
Grading and disease management in national screening for diabetic retinopathy in England and Wales
Author(s) -
Harding S.,
Greenwood R.,
Aldington S.,
Gibson J.,
Owens D.,
Taylor R.,
Kohner E.,
Scanlon P.,
Leese G.
Publication year - 2003
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.2003.01077.x
Subject(s) - medicine , diabetic retinopathy , maculopathy , grading (engineering) , retinopathy , optometry , referral , ophthalmology , diabetes mellitus , family medicine , civil engineering , engineering , endocrinology
Aims A National Screening Programme for diabetic eye disease in the UK is in development. We propose a grading and early disease management protocol to detect sight‐threatening diabetic retinopathy and any retinopathy, which will allow precise quality assurance at all steps while minimizing false‐positive referral to the hospital eye service. Methods Expert panel structured discussions between 2000 and 2002 with review of existing evidence and grading classifications. Proposals Principles of the protocol include: separate grading of retinopathy and maculopathy, minimum number of steps, compatible with central monitoring, expandable for established more complex systems and for research, no lesion counting, no ‘questionable’ lesions, attempt to detect focal exudative, diffuse and ischaemic maculopathy and fast track referral from primary or secondary graders. Sight‐threatening diabetic retinopathy is defined as: preproliferative retinopathy or worse, sight‐threatening maculopathy and/or the presence of photocoagulation. In the centrally reported minimum data set retinopathy is graded into four levels: none (R0), background (R1), preproliferative (R2), proliferative (R3). Maculopathy and photocoagulation are graded as absent (M0, P0) or present (M1, P1). Discussion The protocol developed by the Diabetic Retinopathy Grading and Disease Management Working Party represents a new consensus upon which national guidelines can be based leading to the introduction of quality‐assured screening for people with diabetes.